What is Retatrutide?
Retatrutide is an investigational "triple agonist" that activates the GIP, GLP-1 and glucagon receptors simultaneously. It has drawn attention for producing substantial weight reduction in clinical trials and is being studied for obesity and metabolic disease.
Also known as: Reta, LY3437943
How Retatrutide is studied
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
Commonly researched for
Research status
Important considerations
Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision.
Retatrutide — frequently asked questions
An investigational triple GIP/GLP-1/glucagon receptor agonist studied for obesity and metabolic disease. It has drawn attention for strong weight-loss results in trials.
No. It is investigational and in clinical trials — not FDA-approved and not commercially available as a medicine.
It adds glucagon-receptor activity to the incretin mechanisms, targeting three receptors instead of one or two. It remains under study.